300750 CONTEMPORARY AMPEREX TECHNOLOGY CO

Laxxon Medical Announces Development Program for Non-Invasive, 3D Printed Oral GLP-1 Asset, Offering an Alternative to GLP-1 Injections on Market

Laxxon Medical Announces Development Program for Non-Invasive, 3D Printed Oral GLP-1 Asset, Offering an Alternative to GLP-1 Injections on Market

New York, 05/22/2024 / 09:05, EST/EDT - EQS Newswire - Laxxon Medical


announced today the development program for LXM.2, a 3D printed oral glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment of adults and pediatric patients 12 years and older with obesity.

LXM.2 is an enterically coated oral solid tablet consisting of a GLP-1 receptor agonist combined with a permeation enhancer intended to increase bioavailability. The addition of the permeation enhancer was made possible using Laxxon Medical's SPID® (Screen Printed Innovative Drug) platform technology.

"Polypeptides and proteins like GLP-1s are known to have low bioavailability due to the degradation in the GI tract and poor uptake, meaning they need protection from degradation and their absorption benefits from permeation enhancers. Traditionally, it has been difficult to manufacture products containing the permeation enhancer via conventional methods, such as direct compression or granulation, given its physicochemical properties. It has additionally been challenging for these traditional manufacturing methods to apply an enteric coating to the finished product." said Dr. Achim Schneeberger, Laxxon Medical's Chief Scientific Officer. "SPID®-Technology is not only characterized by precise and tailored dosing - its unique formulation allows manufacturing of oral solids containing clinically relevant doses of permeation enhancers at convincing hardness and low friability."

The active pharmaceutical ingredient (API) in LXM.2 has already been approved by the FDA for use in adults and pediatric patients 12 years and older with obesity. LXM.2 is eligible to be developed using the 505(b)2 pathway. Laxxon has designed a streamlined development program and is targeting an NDA submission in early 2027.

Laxxon Medical CEO Helmut Kerschbaumer said: "LXM.2 would be a game-changer for patients struggling with obesity. Injectable medications, while effective, can be inconvenient and pose a barrier for some people. An oral option would offer greater ease of use and potentially improve adherence to treatment. This could significantly increase the number of patients who can successfully manage their weight and achieve long-term health benefits. The ability to use the 505(b)2 pathway means we can potentially get LXM.2 to patients quickly."

Laxxon is seeking to partner or out-license LXM.2. A team of Laxxon Medical representatives will be attending BIO in San Diego, June 3-8, 2024.

Read more about LXM.2 .

About Laxxon Medical

Laxxon Medical is a pharma-technology company pioneering a new generation of advanced pharmaceuticals with SPID®, a novel 3D screen printing platform technology. For new and common pharmaceutical drugs, SPID® unlocks innovative drug delivery advancements paired with fast-tracked market access and extensive IP protection to yield disruptive opportunities for partners and life-changing results for patients.

Laxxon's pipeline includes ongoing working-projects with notable pharma players, biotech companies and research universities, in addition to 13 in-house Advanced Patented Generics products. Laxxon's IP is continuously growing and consists of 150 patents and patent applications with more than 3,000 patent claims.

Investor Contact: Alexander Ruckdaeschel, Chief Strategy Director

Business Development Contact: Jessica McHargue, Director of Business Development

Media Contact: Frances Hoggard, Communications Manager

SOURCE: Laxxon Medical



05/22/2024 EQS Newswire / EQS Group AG



fncls.ssp?fn=show_t_gif&application_id=1908961&application_name=news&site_id=research_pool
EN
22/05/2024

Underlying

300750CONTEMPORARY AMPEREX TECHNOLOGY CO

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CONTEMPORARY AMPEREX TECHNOLOGY CO

 PRESS RELEASE

The Success of Global Cement and Concrete Association (GCCA) CEO Gathe...

EQS Newswire / 13/06/2024 / 17:30 CET/CEST Cementing Global Government and Industry Partnership, Securing Green Fund to Propel Thai Cement Industry Towards Net Zero Future BANGKOK, THAILAND - - 13 June 2024 - Global Cement and Concrete Association (GCCA) in collaboration with Thai Cement Manufacturers Association (TCMA) successfully hosted "GCCA CEO Gathering and Leader Conference 2024", the first cement and concrete industry summit in Thailand. This conference marks a significant milestone in uniting efforts from governments, international organizations and alliances of leading cement...

 PRESS RELEASE

EQS-News: Dr Ingo Mantzke has resigned as Chairman of the Advisory Boa...

Issuer: PeopleNet Capital GmbH / Key word(s): Personnel Dr Ingo Mantzke has resigned as Chairman of the Advisory Board of Swiss Merchant Group AG 13.06.2024 / 11:15 CET/CEST The issuer is solely responsible for the content of this announcement. Press Release   Frankfurt am Main, 13.06.2024   Dr Ingo Mantzke has resigned as Chairman of the Advisory Board of Swiss Merchant Group AG   Dr. Ingo Mantzke, Owner/CEO, PeopleNet Capital GmbH, has resigned from his free of charge mandate as Chairman of the Advisory Board of Swiss Merchant Group AG, effective April 30, 2024. ...

 PRESS RELEASE

EQS-News: Dr. Ingo Mantzke hat Mandat als Vorsitzender des Beirates de...

Emittent / Herausgeber: PeopleNet Capital GmbH / Schlagwort(e): Personalie Dr. Ingo Mantzke hat Mandat als Vorsitzender des Beirates der Swiss Merchant Group AG niedergelegt 13.06.2024 / 11:15 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Pressemitteilung   Frankfurt am Main, 13.06.2024   Dr. Ingo Mantzke hat Mandat als Vorsitzender des Beirates der Swiss Merchant Group AG niedergelegt   Dr. Ingo Mantzke, Geschäftsführender Gesellschafter der PeopleNet Capital GmbH, hat mit Wirkung zum 30.4.2024 sein unentgeltliches Mandat als...

 PRESS RELEASE

Les droits de douane sur les voitures électriques chinoises ne font qu...

auto-schweiz / Mot-clé(s) : Autres Les droits de douane sur les voitures électriques chinoises ne font que des perdants 12.06.2024 / 17:21 CET/CEST Annonce de l'UE Berne, 12 juin 2024 Auto-suisse prend note avec inquiétude de l'annonce faite aujourd'hui par la Commission européenne d'imposer provisoirement, à partir du 4 juillet, des droits de douane supplémentaires élevés pouvant aller jusqu'à 38,1 % sur les voitures de tourisme à propulsion électrique fabriquées par des constructeurs chinois. Après l'annonce par l'administration Biden du quadruplement (de 25 à 100 %) des ...

 PRESS RELEASE

EQS-News: Pineapple German Bidco GmbH legt die Barabfindung für den Sq...

EQS-News: EQS Group AG / Schlagwort(e): Squeeze-Out Pineapple German Bidco GmbH legt die Barabfindung für den Squeeze-Out bei der EQS Group AG auf EUR 40 je Aktie fest 12.06.2024 / 17:15 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. München, 12. Juni 2024 – Die Pineapple German Bidco GmbH, eine Holdinggesellschaft, die von Fonds kontrolliert wird, die von Thoma Bravo, L.P. verwaltet und/oder beraten werden, hat heute ihr Verlangen vom 1. März 2024 auf Übertragung der Aktien der übrigen Aktionäre der EQS Group AG (Minderheitsaktionär...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch